Sanofi announces end of program evaluating tusamitamab ravtansine after a 2L NSCLC Phase 3 trial did not meet a primary endpoint
from Sanofi - Aventis Groupe https://ift.tt/XGJmAoH
via IFTTT
Press Release: Sanofi announces end of program evaluating tusamitamab ravtansine after a 2L NSCLC Phase 3 trial did not meet a primary endpoint
https://ift.tt/os9kIx3
from Sanofi - Aventis Groupe https://ift.tt/XGJmAoH
via IFTTT
from Sanofi - Aventis Groupe https://ift.tt/XGJmAoH
via IFTTT
Tags:
Posted by: Nitesh sinha
You may like these posts
health-issuePress Release: Dupixent recommended for EU approval by the CHMP to treat eosinophilic esophagitis in children as young as 1 year old
- health-issue
Press Release: Tolebrutinib demonstrated a 31% delay in time to onset of confirmed disability progression in non-relapsing secondary progressive multiple sclerosis phase 3 study
- health-issue
Press Release: Sanofi, RadioMedix, and Orano Med announce licensing agreement on next-generation radioligand medicine for rare cancers
0 Comments
Please ,
Do not enter any kind of span link